Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Market Closed 12-19 16:00:00 EST

199.99

+0.19

+0.10%

盘后199.50

-0.49-0.25%

18:07 EST

High202.78	Low197.16	Vol1.82M
Open200.67	D1 Closing199.80	Amplitude2.82%
Mkt Cap12.34B	Tradable Cap12.02B	Total Shares61.70M
T/O363.52M	T/O Rate3.02%	Tradable Shares60.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":199.99,"timestamp":1766178000000,"preClose":199.8,"halted":0,"volume":1816623,"hourTrading":{"tag":"盘后","latestPrice":199.5,"preClose":199.99,"latestTime":"18:07 EST","volume":253621,"amount":50720991.165,"timestamp":1766185631128},"delay":0,"floatShares":60083367,"shares":61695200,"eps":-4.538371,"marketStatus":"Market Closed","change":0.19,"latestTime":"12-19 16:00:00 EST","open":200.67,"high":202.78,"low":197.155,"amount":363523738.21326,"amplitude":0.028153,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.538371,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":199.8,"preHourTrading":{"tag":"盘前","latestPrice":206.7006,"preClose":199.8,"latestTime":"08:28 EST","volume":15,"amount":3071.29005,"timestamp":1766150913144},"postHourTrading":{"tag":"盘后","latestPrice":199.5,"preClose":199.99,"latestTime":"18:07 EST","volume":253621,"amount":50720991.165,"timestamp":1766185631128},"volumeRatio":2.1096475607942105,"impliedVol":0.4963,"impliedVolPercentile":0.728},"requestUrl":"/m/hq/s/ASND","defaultTab":"news","newsList":[{"id":"2592888661","title":"European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2592888661","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592888661?lang=en_us&edition=fundamental","pubTime":"2025-12-19 00:05","pubTimestamp":1766073950,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Thursday morning, rising 0.63% to 1,651.45 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by 3D printer company Materialise  and accommodations booking site trivago , which rose 5.6% and 4.8%, respectively. They were followed by biopharmaceutical company Cellectis  and semiconductor company Sequans Communications , which increased 3.9% and 2%, respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and furniture manufacturer Natuzzi , which dropped 6.6% and 5%, respectively. They were followed by biopharmaceutical company argenx  and pharmaceutical company Ascendis Pharma , which lost 1.4% and 1.1%, respectively.From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech  and biopharmaceutical company Mereo BioPharma Group , which advanced 4.1% and 2.9%, respectively. They were followed by bio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MREO","BCYC","ARGX","AFG","LU2324357040.USD","LU0320765646.SGD","BK4207","BK4505","LU0320765992.SGD","LU0162691827.USD","BK4007","BK4201","IE00B2B36J28.USD","IE00BJT1NW94.SGD","MTLS","BK4077","BK4023","ASND","BCS","CLLS","DBVT","LU1983260115.SGD","BK4082","NTZ","AMRN","LU0109394709.USD","LU1162221912.USD","BK4107","IE0034235188.USD","TRIB","BK4141","BK4585","SQNS","BK4139","BK4521","TRVG","LU1829250122.USD","BK4546","IE00BFTCPJ56.SGD","BDRX","BK4588","IE00BJJMRZ35.SGD","BP","IE0002141913.USD","BK4095","LU0889565916.HKD","AKTX","LU0072461881.USD","IE00B4R5TH58.HKD","IE0009355771.USD"],"gpt_icon":0},{"id":"2591830688","title":"European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2591830688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591830688?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:17","pubTimestamp":1765556266,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending lower late Friday morning, falling 1% to 1,646.41 on the S&P Europe Select ADR Index, which is up 1.3% so far this week","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","IE00BZ1G4Q59.USD","IE00BMPRXN33.USD","AKTX","BK4075","BK4117","ASND","BTI.AU","NOK","LU0006061336.USD","BDRX","BK4207","BK4532","BK7104","BK4134","LYG","LU1093756325.SGD","LU0084288595.USD","EDAP","DAVA","LU0109394709.USD","PUK","IE00BKVL7J92.USD","TEF","BK4142","BK4588","LU1093756168.USD","BK7062","BTI","LU2543165471.USD","NVO.AU","DBVT","LU0154236417.USD","LU0648005311.SGD","BK4020","EQNR","BK4107","DAVA.AU","AUTL","BK4162","BK4082","IHG","CLLS","AFG","BK4115","LU0320765992.SGD","BK4521","BK4547","BK4139"],"gpt_icon":1},{"id":"2590349420","title":"Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349420","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349420?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:16","pubTimestamp":1765286160,"startTime":"0","endTime":"0","summary":"Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's Halftime Report. FDA extended review for TransCon CNP.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Analyst.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Analyst.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/25/12/49277738/monolithic-power-ascendis-pharma-and-more-cnbcs-final-trades","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/25/12/49277738/monolithic-power-ascendis-pharma-and-more-cnbcs-final-trades","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU1852331112.SGD","LU0353189763.USD","IE00BN0W2V16.EUR","LU2087625088.SGD","LU1861215975.USD","LU2272731865.HKD","BK4588","LU1861220033.SGD","IE00BN0W2W23.USD","LU0109391861.USD","LU2322448957.HKD","LU2250418816.HKD","LU0353189680.USD","MPWR","LU1992135399.USD","IE00BN0W2T93.GBP","LU0081259029.USD","LU0109394709.USD","BK4139","LU1267930730.SGD","LU0708995401.HKD","LU2290526834.HKD","ASND","LU2272731782.SGD","BK4141","IE00BD6J9T35.USD","LU0274383776.USD","LU2360107168.USD","LU1992135472.HKD","LU2360106780.USD","LU2322448791.USD","LU0056508442.USD","LU0320765059.SGD","BK4585","LU2089985449.USD","LU0672654240.SGD","LU2473716301.USD","LU2931357623.SGD","LU2272731600.USD"],"gpt_icon":0},{"id":"2589497398","title":"Biotech Is Healthier Than Investors Think -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2589497398","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589497398?lang=en_us&edition=fundamental","pubTime":"2025-12-06 10:30","pubTimestamp":1764988200,"startTime":"0","endTime":"0","summary":"If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster for investors.The ETF, which trades under the ticker XBI, collapsed in February 2021 as the early-pandemic-era enthusiasm for biotech dissipated like air from a popping balloon. It was more or less moribund until this past summer, when biotech stocks began to rebound, apparently driven by an easing of investor worries over the Trump administration's efforts to reduce drug prices and a marketwide shift toward riskier sectors.RA Capital, which Kolchinsky co-founded in 2004, started as a biotech-focused hedge fund. It has since expanded its focus and now invests in private biotechs and even forms start-ups of its own. It calls itself a multistage investment manager and says it had $13.3 billion under management as of the end of October.Some were getting acquired, and some were launching thei","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU0098860793.USD","LU2089984988.USD","LU0203345920.USD","LU0211331839.USD","IE00BN8TJ469.HKD","LU0109394709.USD","LU1093756168.USD","LU2361044949.HKD","SG9999014542.SGD","SG9999015358.SGD","LU1066051225.USD","SG9999002224.SGD","LU1116320737.USD","IE000M9KFDE8.USD","LU0265550946.USD","BK4585","BK4533","BK4581","LU1162221912.USD","LU0861579265.USD","LU0006306889.USD","BK4534","LU1941712348.USD","BK4211","LU1941712264.USD","LU0265550359.USD","LU0070302665.USD","LU1037948897.HKD","LU0320765992.SGD","LU2361044865.SGD","BK4139","LU1989772840.SGD","LU2461242641.AUD","SG9999013999.USD","LU0266013472.USD","LU1934455277.USD","LU2023250843.SGD","SG9999014559.SGD","BK4559","LU1066051811.HKD","IE00BLSP4239.USD","LU1291159041.SGD","LU0106261372.USD","LU2361045086.USD","LU0122379950.USD","LU0965508806.USD","LU1061106388.HKD","BK4007","LU1983299246.USD","LU0320765646.SGD","LU0289739699.SGD","LU1430594728.SGD","LU2112291526.USD","LU1934455194.USD","BK4550","IE00BSNM7G36.USD","LU1934455863.HKD","SG9999001176.USD","LU1974910355.USD","LU0238689110.USD","LU0234572021.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","SG9999014575.USD","SG9999001440.SGD","LU1093756325.SGD","IE00BBT3K403.USD","LU0965509010.AUD","IE00BFTCPJ56.SGD","LU1037948541.HKD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU2324357040.USD","SG9999002232.USD","IE0002141913.USD","LU1066053197.SGD","LU0320765489.SGD","LU1066051498.USD","LU1023059063.AUD","LU2468319806.SGD","LU0058720904.USD","LU1571399168.USD","LU1585245621.USD","LU1929549753.HKD","LU0965509101.SGD","XBI","LU0985320562.USD","IE0009355771.USD","IE00B4R5TH58.HKD","SGXZ57979304.SGD","IE00B1BXHZ80.USD","LU0965509283.SGD","LU0889565916.HKD","BK4516","BK4588","LU0203347892.USD","LU1917777945.USD","SG9999001176.SGD","LU2106854487.HKD","IE00BLSP4452.SGD","SG9999014567.USD","LU1116320901.HKD","LU1989771016.USD","LU1989772923.USD","LU2023250504.SGD","SG9999015341.SGD","ASND","LU1069347547.HKD","LU1035773651.USD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2589273835","title":"The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589273835","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589273835?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:10","pubTimestamp":1764864600,"startTime":"0","endTime":"0","summary":"If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster for investors.The ETF, which trades under the ticker XBI, collapsed in February 2021 as the early-pandemic-era enthusiasm for biotech dissipated like air from a popping balloon. It was more or less moribund until this past summer, when biotech stocks began to rebound, apparently driven by an easing of investor worries over the Trump administration's efforts to reduce drug prices and a marketwide shift toward riskier sectors.RA Capital, which Kolchinsky co-founded in 2004, started as a biotech-focused hedge fund. It has since expanded its focus and now invests in private biotechs and even forms start-ups of its own. It calls itself a multistage investment manager and says it had $13.3 billion under management as of the end of October.Some were getting acquired, and some were launching thei","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU1941712264.USD","LU1989772923.USD","IE00B2B36J28.USD","BK4585","LU1057294990.SGD","LU1093756168.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","LU2361045086.USD","IE0002141913.USD","ISBC","LU1571399168.USD","LU1291159041.SGD","LU2112291526.USD","LU2461242641.AUD","BK4588","LU0211331839.USD","SG9999014567.USD","LU1989772840.SGD","LU1585245621.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","IE00BBT3K403.USD","LU2468319806.SGD","LU2023250843.SGD","LU2106854487.HKD","LU2023250504.SGD","MRK","XBI","ASND","RYTM","LU0320765992.SGD","LU1066053197.SGD","LU1934455863.HKD","LU1983299246.USD","BK4516","IE00BN8TJ469.HKD","SG9999014559.SGD","LU1066051225.USD","SG9999015341.SGD","LU1037948541.HKD","LU1934455277.USD","CDTX","IE00B1BXHZ80.USD","LU1162221912.USD","LU1061106388.HKD","LU0861579265.USD","SG9999015358.SGD","LU0266013472.USD"],"gpt_icon":0},{"id":"2586368147","title":"Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2586368147","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586368147?lang=en_us&edition=fundamental","pubTime":"2025-11-28 23:13","pubTimestamp":1764342780,"startTime":"0","endTime":"0","summary":"FDA extends Ascendis' TransCon CNP review to Feb. 28, 2026, after new data submission related to post-marketing study requirements.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/28/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/28/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/25/11/49115519/ascendis-pharma-hit-by-fda-delay-as-transcon-cnp-decision-slips-to-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/11/49115519/ascendis-pharma-hit-by-fda-delay-as-transcon-cnp-decision-slips-to-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4588","IE00BD4GTT62.SGD","LU0889565916.HKD","BK4208","IE00BD4GTW91.USD","BK4139","BK4585","LU0109394709.USD","CNP","LU0320765992.SGD","LU2380233275.USD","IE00BD4GTV84.USD","ASND"],"gpt_icon":0},{"id":"2586266977","title":"European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2586266977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586266977?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:03","pubTimestamp":1764172980,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were surging higher late Wednesday morning, rising 1.25% to 1,614.11 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical companies Novo Nordisk  and Ascendis Pharma , which rose 3.5% and 1.8%, respectively. They were followed by biopharmaceutical company DBV Technologies  and lender Banco Santander , which were up 1.7% and 1.6%, respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and brewing company Anheuser-Busch InBev , which fell 4.6% and 1%, respectively. They were followed by biotech firm Evaxion  and pharmaceutical company Sanofi , which were off 0.9% each.From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics  and NuCana , which increased 5.5% and 3.7%, respectively. They were followed by lenders Barclays  and Lloyds Banking Group , which advanced 3.2% each.The decliners from the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NCNA","LU0889565916.HKD","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","AKTX","BK4117","ASND","DGE.UK","MREO","SAN","BK4207","BK4532","BK7104","BCYC","BK4585","BK4599","LU1093756325.SGD","LYG","BCS","LU0109394709.USD","IE00BKVL7J92.USD","EVAX","BK4158","BK4588","LU1093756168.USD","BK4559","DEO","NVO.AU","DBVT","BK7142","LU0154236417.USD","BUD","BK4107","AUTL","SAN.AU","BK7119","BUD.AU","SNY","NVO","BK4505","BK4169","AFG","CLLS","LU0320765992.SGD","BK4521","BK4007","BK4139"],"gpt_icon":1},{"id":"2586251597","title":"Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251597?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:57","pubTimestamp":1764158265,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Ascendis Pharma, with a price target of $254.00. Thom...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-ascendis-pharma-asnd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-ascendis-pharma-asnd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4585","BK4127","BK4139","ASND","LU0109394709.USD","SF","LU0320765992.SGD","CFA"],"gpt_icon":0},{"id":"2586251599","title":"Ascendis Pharma (ASND) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251599","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251599?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:57","pubTimestamp":1764158257,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma, with a price target of $297.00. Archila cove...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","LU1363072403.SGD","IE000M9KFDE8.USD","BK4559","ASND","BK4501","LU0314106906.USD","LU1267930227.SGD","LU1506573853.SGD","LU2461242641.AUD","LU0162691827.USD","LU0256863811.USD","LU2361044865.SGD","LU0154236417.USD","LU0208291251.USD","LU0417517546.SGD","LU0310799852.SGD","LU0942090050.USD","LU2361044949.HKD","LU1267930573.SGD","IE0002270589.USD","LU0477156953.USD","LU0683600562.USD","BK4139","LU0128525929.USD","LU0868494708.USD","LU1280957306.USD","LU0971096721.USD","LU0267386448.USD","LU0130517989.USD","LU0289960550.SGD","LU0106831901.USD","LU1668664300.SGD","BK4207","LU0211328371.USD","LU1035773651.USD","LU0128525689.USD","LU0310800965.SGD","LU1069347547.HKD","LU0070302665.USD","IE00B7SZLL34.SGD","LU1814569148.SGD","LU0149725797.USD","LU1791807156.HKD","BK4504","LU0052756011.USD","LU0320765992.SGD","LU0787776722.HKD","LU0251142724.SGD","LU0648001328.SGD"],"gpt_icon":0},{"id":"2586565352","title":"FDA Extends Review of Ascendis Pharma’s TransCon CNP NDA to February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2586565352","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586565352?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:06","pubTimestamp":1764155167,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S announced that the U.S. Food and Drug Administration  has designated information submitted on November 5, 2025, regarding a post-marketing requirement for the New Drug Application  for TransCon CNP  for children with achondroplasia as a major amendment. As a result, the FDA has extended the Prescription Drug User Fee Act  target action date by three months, with a new decision date set for February 28, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL6w6QW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","ASND","LU0109394709.USD","BK4139","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2586283407","title":"Ascendis Pharma annouces FDA extension for TransCon CN","url":"https://stock-news.laohu8.com/highlight/detail?id=2586283407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586283407?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:20","pubTimestamp":1764112816,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced that the FDA notified the Company that information submitted on November 5 related to the post-marketing requireme...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-annouces-fda-extension-for-transcon-cn-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-annouces-fda-extension-for-transcon-cn-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CN","ASND","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","BK4585"],"gpt_icon":0},{"id":"2584376953","title":"Ascendis Pharma Price Target Maintained With a $220.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2584376953","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584376953?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:05","pubTimestamp":1763474700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 09:05 ET (14:05 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","LU0320765992.SGD","BK4139","LU0109394709.USD","ASND"],"gpt_icon":0},{"id":"2584067459","title":"Ascendis Pharma publishes results from ApproaCH Trial in JAMA Pediatrics","url":"https://stock-news.laohu8.com/highlight/detail?id=2584067459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584067459?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:05","pubTimestamp":1763413508,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigationa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-publishes-results-from-approach-trial-in-jama-pediatrics-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-publishes-results-from-approach-trial-in-jama-pediatrics-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4139","BK4585","LU0320765992.SGD","ASND","LU0109394709.USD"],"gpt_icon":0},{"id":"2584671282","title":"Ascendis Pharma Reports Positive Phase 3 Results for TransCon CNP in Children with Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2584671282","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584671282?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:01","pubTimestamp":1763413277,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S has announced the publication of pivotal Week 52 results from its randomized, double-blind, placebo-controlled ApproaCH Trial of TransCon CNP  in children with achondroplasia. The results, already published in JAMA Pediatrics, show that treatment with TransCon CNP led to significantly higher annualized growth velocity at Week 52 compared to placebo, as well as improvements in lower-limb alignment, body proportionality, and health-related quality of life. The safety and tolerability profile was similar to placebo. TransCon CNP is currently under Priority Review by the U.S. Food & Drug Administration, with a target decision date of November 30, 2025, and is also under review by the European Medicines Agency.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL8CN9p3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","LU0320765992.SGD","NDAQ","LU2210150020.SGD","LU0889565916.HKD","LU2210149790.SGD","BK4588","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","LU0109394709.USD","ASND","BK4139","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584627021","title":"European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2584627021","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584627021?lang=en_us&edition=fundamental","pubTime":"2025-11-18 00:19","pubTimestamp":1763396365,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly lower late Monday morning, edging 0.1% lower to 1,610.86 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and pharmaceutical company Ascendis Pharma , which climbed 7.5% and 7.2%, respectively. They were followed by biopharmaceutical companies DBV Technologies  and Genfit , which advanced 5.4% and 3.5%, respectively.The decliners from continental Europe were led by software firm SAP  and lender Banco Santander , which fell 1.9% each. They were followed by brewing company Anheuser-Busch InBev  and health technology company Philips , which were down 1.6% and 1.4%, respectively.From the UK and Ireland, the gainers were led by communications company WPP  and biopharmaceutical company Mereo BioPharma Group , which rose 11% and 2.5%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics  and pharmaceutical compan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4521","SAN.AU","DBVT","GSK.UK","WPP","AKTX","LU0109394709.USD","BK4505","BK4007","BK4117","CLLS","LU0889565916.HKD","MREO","BDRX","BK4588","BUD","SAN","ASND","BK7142","BK4107","TRIB","LU0320765992.SGD","BK4139","BK7119","BK4613","BK4082","BK4158","SAP","BK4207","LU1829250122.USD","BCYC","BK4532","NCNA","GNFT","BK4528","GNFTY","GSK","BK4585","BK4009","WPP.AU","BUD.AU","PHG","AFG","BK4023"],"gpt_icon":0},{"id":"1135681185","title":"Stock Track | Ascendis Pharma Soars 5.13% in Pre-Market Following Wells Fargo's Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1135681185","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135681185?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:52","pubTimestamp":1763391152,"startTime":"0","endTime":"0","summary":"Shares of Ascendis Pharma A/S (ASND) are surging 5.13% in pre-market trading on Monday, following a positive analyst report from Wells Fargo. The Danish biopharmaceutical company's stock price jump...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ASND"],"gpt_icon":0},{"id":"2584610456","title":"Ascendis Pharma (ASND) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2584610456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584610456?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:35","pubTimestamp":1763364915,"startTime":"0","endTime":"0","summary":"In a report released on November 14, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma, with a price target of $297.00. The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","IE00B7SZLL34.SGD","BK4139","LU0130102774.USD","LU0310800379.SGD","LU0251131958.USD","LU0314106906.USD","IE0002270589.USD","BK4588","BK4504","LU1267930573.SGD","LU0128525689.USD","LU0162691827.USD","LU0154236417.USD","LU0251142724.SGD","LU1069347547.HKD","LU1201861249.SGD","IE00B19Z3B42.SGD","LU0149725797.USD","LU1074936037.SGD","LU0106831901.USD","BK4501","ASND","LU0889565916.HKD","LU0708994859.HKD","LU1267930227.SGD","LU0109394709.USD","LU0310800965.SGD","LU0130517989.USD","IE000M9KFDE8.USD","LU2461242641.AUD","LU1267930490.SGD","LU1280957306.USD","LU0787776722.HKD","LU0072461881.USD","LU0267386448.USD","LU0477156953.USD","LU0320765489.SGD","LU2236285917.USD","LU0128525929.USD","LU0211327993.USD","LU0980610538.SGD","LU2361044865.SGD","LU0320765992.SGD","LU0683600562.USD","LU0742534661.SGD","LU1791807156.HKD","LU1506573853.SGD","LU0640476718.USD","BK4559"],"gpt_icon":0},{"id":"2583263175","title":"How Investors Are Reacting To Ascendis Pharma (ASND) Achieving First Positive Operating Income and Pooled Data Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2583263175","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583263175?lang=en_us&edition=fundamental","pubTime":"2025-11-15 11:35","pubTimestamp":1763177702,"startTime":"0","endTime":"0","summary":"Ascendis Pharma reported third-quarter 2025 results showing revenue of €213.63 million and a net loss of €60.99 million, with improved financial performance, global expansion of key products like YORVIPATH and Skytrofa, and ongoing regulatory progress for its pipeline therapy TransCon CNP.\nA new pooled analysis revealed sustained three-year improvements in renal function and safety for adults with hypoparathyroidism treated with TransCon PTH, emphasizing the clinical value supporting product...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/how-investors-are-reacting-to-ascendis-pharma-asnd-achieving","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/how-investors-are-reacting-to-ascendis-pharma-asnd-achieving","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ASND","ISBC"],"gpt_icon":0},{"id":"1190537841","title":"Stock Track | Ascendis Pharma Soars 5.49% Amid Positive Analyst Sentiment and ADR Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1190537841","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190537841?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:06","pubTimestamp":1763136380,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) saw its stock soar 5.49% in Friday's trading session, outperforming the broader market and emerging as a standout among European equities traded as American Depositary...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ASND"],"gpt_icon":0},{"id":"2583925335","title":"Morgan Stanley Reaffirms Their Buy Rating on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583925335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583925335?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:55","pubTimestamp":1763049337,"startTime":"0","endTime":"0","summary":"In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Ascendis Pharma, with a price target of $250.00. According ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-reaffirms-their-buy-rating-on-ascendis-pharma-asnd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-reaffirms-their-buy-rating-on-ascendis-pharma-asnd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":-0.0927},{"period":"1month","weight":-0.0573},{"period":"3month","weight":0.0117},{"period":"6month","weight":0.1305},{"period":"1year","weight":0.4519},{"period":"ytd","weight":0.4527}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.028378},{"month":2,"riseRate":0.545455,"avgChangeRate":0.052339},{"month":3,"riseRate":0.454545,"avgChangeRate":0.035071},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.034117},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.003499},{"month":6,"riseRate":0.636364,"avgChangeRate":0.020914},{"month":7,"riseRate":0.636364,"avgChangeRate":0.000335},{"month":8,"riseRate":0.727273,"avgChangeRate":0.084941},{"month":9,"riseRate":0.636364,"avgChangeRate":0.039794},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.00981},{"month":11,"riseRate":0.818182,"avgChangeRate":0.047363},{"month":12,"riseRate":0.454545,"avgChangeRate":0.036308}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction